Cullinan Mica Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 2

Cullinan Mica General Information

Description

Developer of a monoclonal antibody designed to reinvigorate the axis into human clinical testing. The company's antibody is predicated on distributing risk while maximizing the optionality inherent in novel science through the construction of a diversified portfolio of internally developed as well as externally sourced oncology assets, enabling physicians to broadly engage natural killer cells and certain lymphocyte populations for tumor cell lysis.

Contact Information

Formerly Known As
PDI Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • One Main Street
  • Suite 520
  • Cambridge, MA 02142
  • United States
+1 (617)
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • One Main Street
  • Suite 520
  • Cambridge, MA 02142
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cullinan Mica Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Secondary Transaction - Private 12-Apr-2024 Completed Startup
3. Secondary Transaction - Private 25-Oct-2022 Completed Startup
2. Later Stage VC 21-Mar-2022 $10M $36M Completed Startup
1. Later Stage VC (Series A) 11-Jun-2020 $26M $26M Completed Startup
To view Cullinan Mica’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Cullinan Mica Patents

Cullinan Mica Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024277733-A1 Methods of treating cancer with anti-mica/b antibodies Pending 24-May-2023
EP-4720128-A2 Methods of treating cancer with anti-mica/b antibodies Inactive 24-May-2023
US-20260317426-A1 Methods of treating cancer with anti-mica/b antibodies Pending 24-May-2023
WO-2024243255-A2 Methods of treating cancer with anti-mica/b antibodies Inactive 24-May-2023
WO-2024243255-A3 Methods of treating cancer with anti-mica/b antibodies Inactive 24-May-2023 C07K16/2833
To view Cullinan Mica’s complete patent history, request access »

Cullinan Mica Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Cullinan Therapeutics Corporation Minority
MMRF Venture Venture Capital Minority
To view Cullinan Mica’s complete investors history, request access »

Cullinan Mica FAQs

  • When was Cullinan Mica founded?

    Cullinan Mica was founded in 2015.

  • Where is Cullinan Mica headquartered?

    Cullinan Mica is headquartered in Cambridge, MA.

  • What industry is Cullinan Mica in?

    Cullinan Mica’s primary industry is Drug Delivery.

  • Is Cullinan Mica a private or public company?

    Cullinan Mica is a Private company.

  • What is Cullinan Mica’s current revenue?

    The current revenue for Cullinan Mica is .

  • How much funding has Cullinan Mica raised over time?

    Cullinan Mica has raised $36M.

  • Who are Cullinan Mica’s investors?

    Cullinan Therapeutics and MMRF Venture have invested in Cullinan Mica.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process